NCT03670069终止1 期
A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib on the Sarcoma Tumor Immune Microenvironment
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Difference in the percentage of cells which are immune inhibitory (CD11B+, CD163+) macrophages from pre-treatment to first post-treatment biopsy
研究概览
简要总结
This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic). Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
详细描述
OUTLINE:
Patients receive itacitinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 7 and 30 days, every 12 weeks from baseline for up to 1 year, and then every 6 months thereafter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects >= 18 years old
- •Must have a histologically confirmed diagnosis of sarcoma with one of the following subtypes:
- •Cohort 1: Leiomyosarcoma
- •Cohort 2: Undifferentiated pleiomorphic sarcoma
- •Cohort 3: Synovial sarcoma or myxoid/round cell liposarcoma
- •Cohort 4: Chondrosarcoma (all subtypes of chondrosarcoma are allowed)
- •Subjects enrolling to cohorts 1, 2, or 3 must have received at least two prior lines of systemic therapy. Subjects enrolling to cohort 4 only may have received any number of prior lines of systemic therapy or may be treatment naïve
- •All ongoing toxicities related to prior therapies must be resolved to grade 1 or better (except alopecia)
- •Subjects must have one or more measurable lesions, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 assessed by computed tomography (CT) or magnetic resonance imaging (MRI)
- •Subjects must have at least one superficial lesion accessible for multiple biopsies; the tumor being biopsied cannot have been previously targeted for radiation therapy or have previously received intra-lesional treatment
- •* NOTE: Superficial lesions previously targeted with radiation therapy that have demonstrated significant new growth via radiological imaging may be targeted for biopsy, with sponsor-investigator approval.
- •Total bilirubin level =< 1.5 x the upper limit of normal (ULN) range mg/dL
- •Aspartate aminotransferase (AST) =< 2.5 x ULN and alanine aminotransferase (ALT) levels =< 2.5 x ULN
- •Alkaline phosphatase < 2.5 x ULN
- •Serum creatinine =< 1.5 x ULN
- •Calculated creatinine clearance >= 30 mL/min using the Cockcroft-Gault formula may be included
- •Absolute neutrophil count (ANC) >= 1.5 × 10^9/L
- •Platelet count >= 100 x 10^9/L; transfusion is permitted as clinically indicated
- •Hemoglobin >= 9 g/dL
- •* Transfusion is permitted as clinically indicated
- •Subjects must have a life expectancy >= 6 months, as determined by the treating physician
- •Eastern Cooperative Oncology Group (ECOG) performance status =< 2 or Karnofksy performance status >= 60
- •Male or non-pregnant and non-breast feeding female:
- •Females of child-bearing potential must agree to use highly effective contraception without interruption from initiation of therapy and while on study medication and have a negative serum pregnancy test (beta - human chorionic gonadotropin [hCG]) result at screening and agree to ongoing pregnancy testing during the course of the study, and at the end of study treatment; a highly effective method of contraception is defined as one that results in a low failure rate (that is, < 1% per year), when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner
- •Male subjects must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study
- •Ability to understand and sign informed consent document
- •Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures
排除标准
- •Known active, uncontrolled, or symptomatic central nervous system (CNS) metastases; a subject with controlled and asymptomatic CNS metastases may participate in this study; as such, the subject must have completed any prior treatment for CNS metastases >= 28 days (including radiotherapy and/or surgery) prior to the start of treatment in this study and should not be receiving chronic corticosteroid therapy for CNS metastases; subjects with known CNS metastases must be confirmed radiographically stable by at least one imaging study, at least 28 days from last treatment
- •Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within 2 weeks of enrollment
- •Prior treatment with a drug targeting JAK1, JAK1/2 or STAT3 inhibitor; Food and Drug Administration (FDA) approved small molecule tyrosine kinase inhibitors (TKIs) not specifically designed to target this pathway are okay (e.g. pazopanib, sunitinib, sorafenib)
- •Known, active drug or alcohol abuse
- •Pregnant or lactating females
- •Active or recent infection requiring systemic anti-infective treatment that was completed =< 14 days prior to enrollment (with the exception of uncomplicated urinary tract infection or upper respiratory infection)
- •Uncontrolled or concurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Oral steroid usage within =< 14 days prior to enrollment
- •Known inflammatory or autoimmune disease which requires patient to occasionally require high dose oral steroids
- •Subjects with known, active human immunodeficiency virus (HIV) infection (subjects with undetectable viral load and normal CD4+ T-cell count are permitted)
- •Inability to swallow food or tablets, or significant gastrointestinal disorder that, in the opinion of the investigator, could interfere with absorption of the study drug
- •Previous reaction to any component of itacitinib or known hypersensitivity to the active substance or any of the excipients
- •Subjects with a sarcoma which has other, defined treatments or biology distinctly different from those of soft tissue sarcomas in general; including, but not limited to, Ewing's sarcoma, rhabdomyosarcoma, gastrointestinal stromal tumors, Kaposi's sarcoma, Wilm's tumor
研究组 & 干预措施
Treatment (itacitinib)
Experimental
Patients receive itacitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Itacitinib (Drug)
Treatment (itacitinib)
Experimental
Patients receive itacitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
结局指标
主要结局
Difference in the percentage of cells which are immune inhibitory (CD11B+, CD163+) macrophages from pre-treatment to first post-treatment biopsy
时间窗: From baseline to 2 years
Evaluation of the change in percentages of cells against the null hypothesis of no difference will be performed using a 1-sided t-test at the 0.05 level.
次要结局
- Incidence of adverse events(Up to 2 years)
- Progression-free survival rate(At 6 months)
- Median overall survival(At 12 months)
- Clinical benefit rate (complete response [CR]+ partial response [PR]+stable disease [SD])(At 12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Itacitinib in Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT04358185Imperial College London19
已完成
1 期
Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic FunctionHealthy SubjectsHepatic InsufficiencyNCT04993404Suzhou Zelgen Biopharmaceuticals Co.,Ltd24
招募中
2 期
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary MyelofibrosisPrimary MyelofibrosisSecondary MyelofibrosisNCT04370301Fred Hutchinson Cancer Center20
终止
2 期
Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal CancerColorectal CancerNCT02277093Washington University School of Medicine11
进行中（未招募）
1 期
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsLeukemia, AcuteMyelodysplastic SyndromesMyelomonocytic Leukemia, ChronicT-cell Prolymphocytic LeukemiaCMLMyeloproliferative DisordersMultiple MyelomaPlasma Cell LeukemiaNCT05823571Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins32